Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atherosclerosis of Extremities Clear all
No Longer Available No phase listed Expanded access

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03886506
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 99 Years
U.S. locations
2
States / cities
Clifton, New Jersey • Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 4:51 AM EDT
Recruiting No phase listed Observational

CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

NCT05145478
View directory record Official record
Conditions
Femoral Arterial Calcification, Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
Interventions
Shockwave Intravascular Lithotripsy (IVL)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 28, 2026, 4:51 AM EDT
Not listed Phase 1 Interventional

The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion During Exercise in Patients With PAD

NCT05036213
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Diseases
Interventions
BEET IT - Concentrate Beet root juice, BEET IT - Concentrate Beet root juice (nitrate depleted)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 28, 2026, 4:51 AM EDT
Not listed Phase 2 Interventional

UT-15C SR in the Treatment of Critical Limb Ischemia

NCT00445159
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
UT-15C SR (treprostinil diethanolamine) 1mg oral tablets
Drug
Lead sponsor
Southern Arizona Vascular Institute
Other
Eligibility
45 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Tucson, Arizona • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2007 · Synced Sep 28, 2026, 4:51 AM EDT
Active, not recruiting Not applicable Interventional Results available

LIFE-BTK Randomized Controlled Trial

NCT04227899
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
Esprit BTK Device, Percutaneous Transluminal Angioplasty (PTA) Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Deer Park, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 28, 2026, 4:51 AM EDT
Not listed Not applicable Interventional

Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia

NCT02234778
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
TGI SVF material via intramuscular injection
Device
Lead sponsor
Tissue Genesis
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 28, 2026, 4:51 AM EDT
Terminated Phase 1 Interventional

Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease

NCT00913900
View directory record Official record
Conditions
Critical Limb Ischemia, Arterial Occlusive Disease, Vascular Diseases
Interventions
autologous CD133+ cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Not applicable Interventional

The COPPER-B Trial

NCT02395744
View directory record Official record
Conditions
Cardiovascular Diseases, Peripheral Vascular Disease, Arterial Occlusive Diseases, Peripheral Arterial Disease, Critical Limb Ischemia
Interventions
Paclitaxel administration using the OPC
Other
Lead sponsor
Horizons International Peripheral Group
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Fairhope, Alabama • Houma, Louisiana • Dearborn, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 28, 2026, 4:51 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

NCT00067041
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Remodulin (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
4
States / cities
Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 28, 2026, 4:51 AM EDT
Completed No phase listed Observational

Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"

NCT02786173
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
Not listed
Lead sponsor
Metro Health, Michigan
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
Orlando, Florida • Springfield, Illinois • Wyoming, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Phase 1Phase 2 Interventional

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

NCT00616980
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
CD34-positive cells, Saline and 5% autologous plasma
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Gainsville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Sep 28, 2026, 4:51 AM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

NCT01049919
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
Bone marrow concentration device, Placebo procedure (sham)
Device · Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
25
States / cities
Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Early Phase 1 Interventional Results available

N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes

NCT03253328
View directory record Official record
Conditions
Diabetes Mellitus, Critical Limb Ischemia, Lower Limb Amputation Knee, Peripheral Arterial Disease
Interventions
Active Arm N-acetyl cysteine (NAC), Placebo Arm
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years to 90 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Not applicable Interventional Results available

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

NCT02574481
View directory record Official record
Conditions
Atherosclerosis of Native Arteries of the Extremities
Interventions
ELUVIA (Stent Implantation), Zilver PTX (Stent Implantation)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
42
States / cities
Yuma, Arizona • Sacramento, California • Gainesville, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 28, 2026, 4:51 AM EDT
Completed No phase listed Observational

Observational Study to Assess Transradial Access for Treatment in the Lower Extremities.

NCT04371861
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Peripheral Artery Treatment
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
La Jolla, California • St. Petersburg, Florida • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Not applicable Interventional

Ischemic Preconditioning Claudication Study

NCT03511157
View directory record Official record
Conditions
Intermittent Claudication, Ischemia Vascular, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
Ischemic Preconditioning, Control Group
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 28, 2026, 4:51 AM EDT
Terminated Phase 3 Interventional Results available

The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

NCT04007055
View directory record Official record
Conditions
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease, Peripheral Arterial Occlusive Disease
Interventions
Point of care screening for HPR, Ticagrelor 90mg
Diagnostic Test · Drug
Lead sponsor
Marissa Jarosinski
Other
Eligibility
18 Years to 90 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Not applicable Interventional

A Non-significant Risk Clinical Study to Assess Perfusion Changes With Application of a TUS for Patients With PAD

NCT05100745
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Therapeutic Device
Device
Lead sponsor
Vibrato Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 28, 2026, 4:51 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia

NCT02144610
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
HGF Plasmid (AMG0001), Matching Placebo
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 28, 2026, 4:51 AM EDT
Completed No phase listed Observational

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia

NCT02974179
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Subjects from Study AG-CLI-0206 who received AMG0001
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Not applicable Interventional Results available

Evaluation of WIRION™ EPS in Lower Extremities Arteries

NCT02780349
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
WIRION
Device
Lead sponsor
Gardia Medical
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Denver, Colorado • Davenport, Iowa • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

NCT03680105
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
RJX, Placebo
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 28, 2026, 4:51 AM EDT
Completed No phase listed Observational Results available

Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease

NCT04229563
View directory record Official record
Conditions
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
Interventions
AURYON Atherectomy System
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Davenport, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 28, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

NCT01064440
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Low Dose VM202, High Dose VM202, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 28, 2026, 4:51 AM EDT